Allogene Therapeutics develops engineered T cell treatments from healthy donor cells for cancer and autoimmune diseases. It last closed at $0.74 on Nov 17, down 7.79% on the day. ALLO last reported earnings on Wed, Aug 12, 2026. In the past 30 days there were 4 dark pool prints totaling $1.5M, the largest $1.1M.
ALLO · as of the Nov 17 close · updated after every close
Downtrend, oversold
The stock is 46% below its 20 day and 84% below its 50 day average. It is 161% below its 200 day average, so the longer trend is down. Momentum is weak (RSI 21), oversold. The nearest support is the 52 week low at $0.74, and the nearest resistance the Pivot at $0.77.
Short trendBearish
Long trendBearish
MomentumWeak
StretchOversold
VolatilityHigh, 12.7%/day
Key levels
$4.4652 week high+502.7%
$1.94200 day average+162.2%
$1.67100 day average+125.7%
$1.3750 day average+85.1%
$1.37Swing high (Oct 21)+85.1%
$1.0820 day average+45.9%
$0.79Pivot R1+6.8%
$0.77Pivot+4.1%
$0.7452 week low+0.0%
$0.74Last close
$0.72Pivot S1−2.7%
Indicators
RSI (14)
21.38
Oversold below 30
Oversold
MACD
-0.17
Below its signal line
Bearish
Stochastic
3.4
Near the bottom of its range
Oversold
ADX (14)
48.3
Strong downtrend
Williams %R
-99.5
Oversold below −80, overbought above −20
Oversold
CCI (20)
-145.5
Oversold below −100, overbought above 100
Oversold
Rate of change
−33.6%
Change over 10 sessions
Bearish
ATR (14)
$0.09
Typical daily range, 12.7% of price
MA 10Below
MA 20Below
MA 50Below
MA 100Below
MA 200Below
Falling, oversold
Short trendBearish
Long trendNot enough history
MomentumWeak
StretchOversold
VolatilityNormal, 33.7%/day
Key levels
$4.4652 week high+502.7%
$1.94200 day average+162.2%
$1.67100 day average+125.7%
$1.3750 day average+85.1%
$1.37Swing high (Oct 21)+85.1%
$1.0820 day average+45.9%
$0.79Pivot R1+6.8%
$0.77Pivot+4.1%
$0.7452 week low+0.0%
$0.74Last close
$0.72Pivot S1−2.7%
Indicators
RSI (14)
22.95
Oversold below 30
Oversold
MACD
-0.27
Below its signal line
Bearish
Stochastic
2.1
Near the bottom of its range
Oversold
ADX (14)
28.5
Trending down
Williams %R
-99.8
Oversold below −80, overbought above −20
Oversold
CCI (20)
-166.9
Oversold below −100, overbought above 100
Oversold
Rate of change
−58.2%
Change over 10 sessions
Bearish
ATR (14)
$0.25
Typical daily range, 33.7% of price
MA 10Below
MA 20Below
MA 50Below
MA 100Below
MA 200–
What happened before, for ALLO
Signal name goes hereSince a recent date
9 times
+0.0%
Signal name goes hereSince a recent date
9 times
+0.0%
Signal name goes hereSince a recent date
9 times
+0.0%
What happened before
See how ALLO did after each of today's signals in the past: how often it was higher 10 sessions later, and the typical move, next to its usual record.
November seasonalityHow ALLO usually does this month. See Seasonality
Calculated from daily prices after each close. Signals describe the chart, not where the stock will go. Past patterns often fail. Not investment advice.
Seasonality
How ALLO has done in each calendar month: the average and median return, how often each month finished higher, and every year since 2018.
From SEC Form 13F filings for Sep 30, 2026. What the filings show, not a forecast: positions can be up to 45 days old and leave out short sales.
AI Auto Pilots
Paper trading
StreetAlpha runs four autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether ALLO is in one of them and how their past ALLO trades turned out.
Allogene Therapeutics is a biotechnology company based in South San Francisco, California, that develops engineered T cell treatments for cancer and autoimmune diseases. Its treatments are made from healthy donor cells, so they can be prepared ahead of time and given to any eligible patient rather than made from each patient's own cells. Its main candidates target lymphoma, kidney cancer and autoimmune conditions such as lupus, and they are in clinical trials with patients as the intended users.